we areramm pharma
A Leader in Medically Registered and Approved Plant Derived Cannabinoid Pharmaceutical Products
Setting the standard with superior processes and products.
RAMM Pharma is a leader in the research and development of cannabinoid pharmaceutical formulations. The company has developed Epifractán™ – Latin America’s first registered cannabinoid pharmaceutical drug. RAMM Pharma has since expanded its array of formulations and products, including approved and registered products that are sold commercially. It also has a pipeline of new products in various stages of approval and development.
RAMM Pharma’s state-of-the-art manufacturing plant is GMP (Good Manufacturing Practices) certified. Its indoor/outdoor grow facilities are ideally located in Uruguay – the most politically, economically and socially stable country in Latin America. Uruguay’s Ministry of Health (MSP) is highly regarded internationally – approval by the MSP can help to fast-track approvals in other countries. The company has established distribution agreements in several key countries and is rapidly establishing additional agreements across Latin America, which has a population of 639 million people.
our brands
pharmaceutical Products
The first cannabinoid pharmaceutical product registered with the Ministry of Health, Epifractán™ (available in 2% and 5% cannabidiol) treats a variety of medical conditions and pathologies.
cosmeceutical Products
Pure CBD active ingredient repairs and relieves many skin conditions, soothes joint pain, and reduces inflammation—all while hydrating the skin.
pharmaceutical Products
The first cannabinoid pharmaceutical product registered with the Ministry of Health, Epifractán™ (available in 2% and 5% cannabidiol) treats a variety of medical conditions and pathologies.
cosmeceutical Products
Pure CBD active ingredient repairs and relieves many skin conditions, soothes joint pain, and reduces inflammation—all while hydrating the skin.
CANNABIS IS BEING ADOPTED GLOBALLY FOR A WIDE RANGE OF MEDICAL CONDITIONS, INCLUDING CHRONIC PAIN FROM CANCER, ARTHRITIS AND HIV/AIDS, EPILEPSY, ANXIETY, DEPRESSION AND MORE.
- RAMM PHARMA
CANNABIS IS BEING ADOPTED GLOBALLY FOR A WIDE RANGE OF MEDICAL CONDITIONS, INCLUDING CHRONIC PAIN FROM CANCER, ARTHRITIS AND HIV/AIDS, EPILEPSY, ANXIETY, DEPRESSION AND MORE.
- RAMM PHARMA
our leadership team
Jack Burnett
Mr. Burnett is a successful entrepreneur with over 40 years’ experience in capital markets and international corporate leadership roles. Mr. Burnett has led companies from inception to acquisition in multiple industries including real estate, insurance and telecom. His deep global business relationships span both private and public markets where he has been a director, officer and majority shareholder of successful companies.
Guillermo Delmonte
Mr. Delmonte is a CPA and proven leader in the international cannabis marketplace. Previously he was the President of the International Division of Organigram (TSX.V:OGI), one of the largest Canadian licensed producers following two and a half years as Director and Chief Executive Officer at ICC Labs, a leading international hemp and cannabis producer. In these roles he successfully oversaw Organigram ́s first international movements and ICC ́s IPO as the first South American cannabis company to become public prior to being acquired by Aurora Cannabis (TSX: ACB). Mr. Delmonte has also held financial and business development leadership roles at BBVA Bank, Technit Group, Credit Agricole Bank, United Nations Uruguay and Bank ITAU.
Jack Burnett
Mr. Burnett is a successful entrepreneur with over 40 years’ experience in capital markets and international corporate leadership roles. Mr. Burnett has led companies from inception to acquisition in multiple industries including real estate, insurance and telecom. His deep global business relationships span both private and public markets where he has been a director, officer and majority shareholder of successful companies.
Guillermo Delmonte
Mr. Delmonte is a CPA and proven leader in the international cannabis marketplace. Previously he was the President of the International Division of Organigram (TSX.V:OGI), one of the largest Canadian licensed producers following two and a half years as Director and Chief Executive Officer at ICC Labs, a leading international hemp and cannabis producer. In these roles he successfully oversaw Organigram ́s first international movements and ICC ́s IPO as the first South American cannabis company to become public prior to being acquired by Aurora Cannabis (TSX: ACB). Mr. Delmonte has also held financial and business development leadership roles at BBVA Bank, Technit Group, Credit Agricole Bank, United Nations Uruguay and Bank ITAU.
Guillermo Varela
Mr. Varela is a Certified Public Accountant and experienced finance professional, with particular expertise in the pharmaceutical and manufacturing sector. Mr. Varela is the former CFO of GrüneLabs, a pharmaceutical laboratory with operations in Europe and South America. Previously he had accounting roles at The Winterbotham Trust Company, CPA Ferrere and Nexia International.
Guillermo Varela
Mr. Varela is a Certified Public Accountant and experienced finance professional, with particular expertise in the pharmaceutical and manufacturing sector. Mr. Varela is the former CFO of GrüneLabs, a pharmaceutical laboratory with operations in Europe and South America. Previously he had accounting roles at The Winterbotham Trust Company, CPA Ferrere and Nexia International.
Guillermo Varela
Mr. Varela is a Certified Public Accountant and experienced finance professional, with particular expertise in the pharmaceutical and manufacturing sector. Mr. Varela is the former CFO of GrüneLabs, a pharmaceutical laboratory with operations in Europe and South America. Previously he had accounting roles at The Winterbotham Trust Company, CPA Ferrere and Nexia International.
Guillermo Varela
Mr. Varela is a Certified Public Accountant and experienced finance professional, with particular expertise in the pharmaceutical and manufacturing sector. Mr. Varela is the former CFO of GrüneLabs, a pharmaceutical laboratory with operations in Europe and South America. Previously he had accounting roles at The Winterbotham Trust Company, CPA Ferrere and Nexia International.
request information
*Required Field.
request information
All fields required.
are you an investor?
learn more about ramm pharma. request an investor package.
A leading researcher and developer of medically approved proprietary cannabinoid formulators and treatments